Claims for Patent: 9,000,011

Summary for Patent: 9,000,011

Title:	Methods for treatment of Fabry disease
Abstract:	Provided are in vitro and in vivo methods for determining whether a patient with Fabry disease will respond to treatment with a specific pharmacological chaperone.
Inventor(s):	Lockhart; David (Del Mar, CA), Castelli; Jeff (New Hope, PA)
Assignee:	Amicus Therapeutics, Inc. (Cranbury, NJ)
Application Number:	13/445,338
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 9,000,011
Patent Claims:	1. A method for treatment of Fabry disease in a patient in need thereof comprising administering to the patient a therapeutically effective dose of 150 mg 1-deoxygalactonojirimycin or a salt thereof every other day. 2. The method of claim 1, wherein 1-deoxygalactonojirimycin or a salt thereof is administered for at least 2 weeks. 3. The method of claim 1, wherein 1-deoxygalactonojirimycin or a salt thereof is administered for at least 6 weeks. 4. The method of claim 1, wherein 1-deoxygalactonojirimycin or a salt thereof is administered for at least 12 weeks. 5. The method of claim 1, wherein the salt of 1-deoxygalactonojirimycin administered is migalastat hydrochloride. 6. The method of claim 1, wherein 1-deoxygalactonojirimycin or a salt thereof is administered orally. 7. A method for enhancing .alpha.-GAL activity in a patient diagnosed with or suspected of having Fabry disease comprising administering to the patient a therapeutically effective dose of 150 mg 1-deoxygalactonojirimycin or a salt thereof every other day. 8. The method of claim 7, wherein 1-deoxygalactonojirimycin or a salt thereof is administered for at least 2 weeks. 9. The method of claim 7, wherein 1deoxygalactonojirimycin or a salt thereof is administered for at least 6 weeks. 10. The method of claim 7, wherein 1-deoxygalactonojirimycin or a salt thereof is administered for at least 12 weeks. 11. The method of claim 7, wherein the salt of 1-deoxygalactonojirimycin administered is migalastat hydrochloride.